Market research
PTGX Protagonist Therapeutics Inc
NASDAQ USD Healthcare
Latest close
As of 30 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 8B
- P/E ratio
- 125.0
- Analyst target
- 178.2143
- Dividend yield
- Not available
- Beta
- 1.52
Profile
Instrument facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- Not available
- Market cap
- 8B
- P/E ratio
- 125.0
- Analyst target
- 178.2143
- Dividend yield
- Not available
- Beta
- 1.52
About
About Protagonist Therapeutics Inc
Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States. It develops Icotyde, a first-in-class investigational targeted oral peptide for the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe plaque psoriasis; and Rusfertide, a first-in-class investigational injectable mimetic of the natural hormone hepcidin in Phase 3 development for the treatment of the rare blood disorder polycythemia vera. The company is also developing PN-881, a potential best-in-class oral peptide IL-17 antagonist, for the treatment of immune-mediated skin diseases in Phase 1 clinical trials; PN-477 and PN-458, which are development candidates for the treatment of obesity; PN-8047, an orally administered hepcidin functional mimetic small molecule; L-4R alpha antagonist for the treatment of atopic dermatitis and moderate-to-severe asthma; and amylinR-based oral and subcutaneous mono- and poly-agonists for the treatment of obesity. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
Research context
Protagonist Therapeutics Inc appears in PyInvesting’s US Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the PTGX discussion.
5 years, 6 months ago
Protagonist Therapeutics, Inc is currently in a long term uptrend where the price is trading 67.6% above its 200 day moving average.
From a valuation standpoint, the stock is 97.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 32.1.
Protagonist Therapeutics, Inc's total revenue rose by 107.8% to $6M since the same quarter in the previous year.
Its net income has dropped by 7.9% to $-19M since the same quarter in the previous year.
Finally, its free cash flow fell by 30.9% to $-19M since the same quarter in the previous year.
Based on the above factors, Protagonist Therapeutics, Inc gets an overall score of 3/5.